Scantox Group Acquires DuplexSeq™ Genomics Safety Business

Scantox Group has announced the acquisition of the nonclinical genomic safety business from TwinStrand Biosciences. This acquisition allows Scantox to become the exclusive provider of DuplexSeq™ Mutagenesis Assays and related nonclinical genomics safety services globally.

This move addresses a growing demand for advanced mutagenesis assessments. The integration of DuplexSeq's advanced sequencing capabilities offers unprecedented accuracy in detecting ultra-rare mutations. Scantox aims to provide these services at a global scale, enhancing its existing Big Blue® transgenic rodent gene mutation assay portfolio into an integrated genomic safety platform.

The technology supports earlier and more confident decisions on mutagenic risks, opening avenues in genetic toxicology, carcinogenicity evaluation, and gene-editing safety. Scantox's expansion reinforces its position as a leader in genomic safety, equipped to meet the industry's advancing demands.